देश: आयरलैंड
भाषा: अंग्रेज़ी
स्रोत: HPRA (Health Products Regulatory Authority)
Triclabendazole
Elanco Europe Ltd
QP52AC01
Triclabendazole
240 milligram(s)/millilitre
Oral suspension
LM: Licensed Merchant as defined in relevant national legislation
Cattle
triclabendazole
Endoparasiticide
Authorised
2008-09-05
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Fasinex 240 mg/ml oral suspension for cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Oral Suspension. White to cream-coloured aqueous suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of acute, subacute and chronic infection due to early immature, immature, and mature stages of _Fasciola hepatica_. If infected animals are treated before disease has developed, fasciolosis can be prevented. 4.3 CONTRAINDICATIONS Do not use in case of hypersensitivity to the active substance or to any of the ingredients. ACTIVE SUBSTANCE: Triclabendazole 240 mg EXCIPIENTS: Methyl parahydroxybenzoate (E218) 1.1 mg Propyl parahydroxybenzoate (E216) 0.4 mg Benzyl alcohol (E1519) 5.0 mg H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _1_ _/_ _1_ _0_ _/_ _2_ _0_ _1_ _6_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _2_ _9_ _9_ _5_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy. Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. Underdosing, which may be due to underestimation of bodyweight, misadministrati पूरा दस्तावेज़ पढ़ें